Tumours with profound copy-number aberration elude molecular stratification due to their genomic complexity. By representing this complexity as a mixture of copy-number signatures, we provide molecular explanations for differing clinical outcomes. Here we present a method for copy-number signature identification, deriving eight signatures in 117 shallow whole-genome sequenced high-grade serous ovarian cancers (HGSOC), which validated on independent cohorts of 95 deep whole-genome sequenced, and 402 SNP array-profiled cases. Three copy-number signatures predicted longer overall survival, while the others predicted poorer outcome. We found evidence for the mutational processes giving rise to copy-number change for six of the eight signatures via correlations with other genomic features. Our results provide insights into the pathogenesis of HGSOC by uncovering multiple mutational processes that shape genomes following TP53 mutation. Importantly, our work shows that most HGSOC have a mixture of mutational processes suggesting that targeting a single mutator phenotype may be therapeutically suboptimal.
Introduction
The discrete mutational processes that drive copy-number change in human cancers are not readily identifiable from genome-wide sequence data. This presents a major challenge for the development of precision medicine for high-grade serous ovarian (HGSOC), oesophageal, small-cell lung and triple negative breast cancers, which are strongly dominated by copy number changes (Ciriello et al., 2013) . These tumours have low frequency of recurrent oncogenic mutations, few recurrent copy number alterations and highly complex genomic profiles (Hoadley et al., 2014) .
HGSOCs are poor prognosis carcinomas with ubiquitous TP53 mutations (Ahmed et al., 2010) . Despite efforts to develop subtype classification approaches, overall survival has not improved over two decades (Vaughan et al., 2011) . Current genomic stratification is limited to defining homologous recombination-deficient (HRD) tumours (Fong et al., 2010; Gelmon et al., 2011; Swisher et al., 2017) , and gene expression classifiers identified by large-scale consortia have not yet demonstrated therapeutic utility (Etemadmoghadam et al., 2009; Verhaak et al., 2013) . Deep whole genome sequencing has revealed gene breakage events targeting RB1, NF1 and PTEN, but has not provided further insights into the underlying mutational processes driving HGSOC (Patch et al., 2015) . Integrated molecular classification has recapitulated the separation of HRD tumours via the enrichment of amplification associated fold-back inversions in non-HRD tumours (Wang et al., 2017) .
Recent algorithmic advances have facilitated interpretation of tumour genome complexity via the identification of mutational signatures -patterns that reflect the mutational processes active during the life of a tumour (Alexandrov et al., 2013) . For example, signatures encoded by single nucleotide variants (SNVs) can represent mutations caused by UV exposure or mismatch repair defects (Alexandrov et al., 2013) , whilst signatures encoded by structural variants (SVs) can represent different types of HRD . Importantly, these studies show that tumours typically have multiple active mutational processes. Quantification of the exposure of a tumour to a particular signature may provide a rational framework to personalise therapy (Davies et al., 2017) . However, accurate quantification currently requires costly whole-genome sequencing for SVs or exome sequencing for SNVs. By contrast, copy-number changes can be interrogated in a cost-effective manner using shallow whole-genome sequencing . Thus, we have developed a method for the identification of copy-number signatures from these data to test the hypothesis that copy-number signatures reflect underlying mutational processes.
Results

Identification and validation of copy-number signatures
To identify copy-number (CN) signatures, we sequenced 300 primary and relapsed HGSOC samples of 142 patients from the BriTROC-1 cohort (Goranova et al., 2017) (Figure 1A ). We combined low-cost shallow whole-genome sequencing (sWGS; 0.1×) with targeted amplicon sequencing of TP53 to generate absolute copy-number profiles. High-quality copy-number profiles from 117 patients were used for copy-number signature identification ( Figure 1B) .
For each sample, we computed the genome-wide distributions of six fundamental CN features: the number of breakpoints per 10MB, the copy-number of segments, the size of segments, the difference in CN between adjacent segments, the distance of breakpoints from the centromere, and the lengths of oscillating CN segment chains. The selection of these features was motivated by hallmarks of previously reported genomic aberrations, including breakage-fusion-bridge cycles (Murnane, 2012) , chromothripsis (Korbel and Campbell, 2013) and tandem duplication (Menghi et al., 2016; Ng et al., 2012) . We summarised each feature using measures of the shape of its distribution: mean, variance, skewness (asymmetry), kurtosis (weight of tails) and modality (number of peaks) resulting in each sample being described by 30 variables.
To identify copy-number signatures from these data, we used non-negative matrix factorisation (NMF) (Lee et al., 2017) , a method previously used for analysing SNV signatures (Alexandrov et al., 2013) . NMF identified eight CN signatures ( Figure 1B) , as well as their defining features and their exposures in each sample. The optimal number of signatures was chosen using a consensus from 1000 initialisations of the algorithm and 1000 random permutations of the data combining four model selection measures ( Figure 2 ). We found highly similar signature variable weights in two independent cohorts of 95 whole-genome sequenced HGSOC samples from ICGC (Campbell et al., 2017) and 402 SNP array profiled HGSOC samples (TCGA, 2011) , thus demonstrating the robustness of our approach (Figure 1B, P<0.005, median r 2 =0.85. Table S1 ).
Using copy-number signatures to predict overall survival Using a combined dataset of 602 samples with full clinical annotation, we explored the association between signature exposures and overall survival ( Figure 3A) . In a multivariate Cox proportional hazards model trained on 356 cases and tested on the remaining 246, CN signatures 1, 7 and 8 had a positive influence on survival, while the remaining five CN signatures had negative influences (Training: P=0.003, log-rank test; stratified by age and cohort; Test: P=0.01, C-index=0.57, 95% CI:0.51-0.62). Significant separation was observed when patients were stratified into good and poor prognosis groups by their dominant signature exposure ( Figure S1 ; Training: P=0.0007, log-rank test; Test: P=0.0003, log-rank test).
Linking copy-number signatures with underlying mutational processes Examination of cases with a predominant single signature showed that CN signatures 1, 7 and 8 were characterised by high genome complexity ( Figure 3B ), with CN signature 7 reminiscent of a tandem duplicator phenotype (Ng et al., 2012) . However, the vast majority of cases exhibited multiple signature exposures indicative of complex phenotypes shaped by several mutational processes ( Figure 3A ). Because our approach breaks down this complexity into its basic constituents, we could begin to characterize the individual contributing mutational processes.
To link individual CN signatures to mutational processes, we used the weights identified by NMF to determine which pattern of global or local copy-number change defined each signature. For example, in CN signature 3, the highest weights were observed for the skewness and kurtosis variables of the breakpoint distance from the centromere feature ( Figure 4 ). This suggested frequent breakpoints close to the end of the chromosomes, which are characteristic of peri-telomeric breaks from breakage-fusion-bridge (BFB) events (Murnane, 2012) . To test this hypothesis, we correlated CN signature 3 exposures with other genomic features across samples that underwent deep WGS ( Figure 5 , Figure S2 , Figure S3 ). CN signature 3 was negatively correlated with telomere length (r 2 =-0.21, P=0.08, multiple testing corrected) and positively correlated with age-associated SNV signature 1 (r 2 =0.35, P=0.0004), consistent with BFB events. In addition, CN signature 3 was positively correlated with amplification-associated fold-back inversion structural variants (r 2 =0.34, P=0.07) that have been associated with inferior survival in HGSOC (Wang et al., 2017) and have been strongly implicated in BFB events (Zakov et al., 2013) . Thus, we believe that BFB is the underlying mechanism for CN signature 3.
We systematically applied the same approach to the remaining signatures to identify other statistically significant genomic associations using a false discovery rate <0.1 ( Figure 5 , Figure 6 , Figure S2 , Figure S3 ). For two CN signatures, 1 and 6, we did not find evidence for specific underlying mechanisms. For three signatures, we identified significant associations with putative canonical signalling pathways, which can inform future mechanistic studies. CN signature 2 was associated with mutations in genes involved in histone deacetylation (P=0.007, one-sided t-test) and lengthening of telomeres (r 2 =0.47, P=3e-05); histone deacetylase (HDAC) activity is closely linked to DNA damage responses (Cea et al., 2016) , specifically via ATM regulation (Thurn et al., 2013) , whilst inhibition of HDACs can induce profound DNA damage (Conti et al., 2010) with upregulation of error-prone non-homologous end-joining (Smith et al., 2014) . CN signature 4 was enriched in cases with oncogenic MAPK signalling involving NF1 loss and mutated KRAS (P=0.003, one-sided t-test) , which has previously been shown to induce chromosomal instability as a result of aberrant G2 and mitotic checkpoint controls and missegregation (Knauf et al., 2006; Saavedra et al., 1999) . CN signature 7 was enriched in patients with high tandem duplicator phenotype scores (r 2 =0.42, P=1e-04) and mutations in the Toll-like receptor (TLR) pathway (P=0.06, one-sided t-test). TLR4 activity regulates expression of Ku70 (Wang et al., 2013) , whilst persistent TLR signalling leads to mitotic defects and potent DNA damage responses (Herrtwich et al., 2016) , suggesting possible links between TLR pathway mutations and CN abnormalities.
For the final two signatures, 5 and 8, we found strong evidence for the underlying mutational processes. CN signature 5 was found at significantly higher exposures (P=1.7e-16, one-sided t-test) in tumours with aberrant cell cycle control, including either amplification of CCNE1, CCND1, CDK4 or MYC , or deletion/inactivation of RB1 . In addition, signature 5 was enriched in tumours with activated PI3K/AKT signalling (P=1.9e-07, one-sided t-test) through mutation of PIK3CA or amplification of EGFR, MET, FGFR3 and ERBB2 , suggesting that the underlying mechanism for this signature is failure of cell cycle control with co-existent oncogenic signalling. Exposure to CN signature 5 was positively correlated with age at diagnosis (r 2 =0.33, P=3e-13) and age-related SNV signature 1 (Alexandrov et al., 2013) (r 2 =0.33, P=5e-04). CN signature 5 was characterised by large values in the copy-number change-point distribution, which suggests that the signature represents a single, late whole-genome duplication event (Zack et al., 2013) . By contrast, CN signature 3 is likely to represent an ongoing process of localised copy-number changes accumulating over multiple cell divisions. CN signatures 5 and 8 had mutually exclusive associations with mutated driver genes and other genomic features ( Figure 5 ). Signature 8 had significantly higher exposures in cases with mutations in BRCA1/2 or other homology-mediated repair (HR) pathway genes (P=1.4e-05, one-sided t-test) and was positively correlated with SNV signature 3 (associated with BRCA1/2 mutations, r 2 =0.53, P=4e-10). It was also negatively correlated both with age at diagnosis (r 2 =-0.23, P=8e-07) and the age-related SNV signature 1 (r 2 =-0.57, P=7e-12), suggesting early age of disease onset. Together, these results are consistent with HR deficiency being the underlying mechanism for signature 8, and confirm previous data showing mutual exclusivity of CCNE1 amplification and defective HR (Etemadmoghadam et al., 2013) , as well as the poor prognosis conferred by cyclin E amplification (Etemadmoghadam et al., 2009 ).
Discussion
Overall, the CN signatures provide a framework that is able to rederive the major defining elements of HGSOC genomes, including defective HR (TCGA, 2011), amplification of cyclin E (Etemadmoghadam et al., 2009) , and amplification-associated fold-back inversions (Wang et al., 2017) . We derived CN signatures using inexpensive shallow whole genome sequencing of DNA from core biopsies, providing a rapid path to clinical implementation. The CN signatures open new avenues for clinical trial design by stratifying patients based upon contributions from BFB, tandem duplicator phenotype, NF1/KRAS and PI3K/AKT signalling.
A major finding is that almost all patients with HGSOC demonstrated a mixture of signatures indicative of combinations of mutational processes. These results suggest that early TP53 mutation, the ubiquitous initiating event in HGSOC, may permit multiple mutational processes to evolve simultaneously. Even in the context of an additional early driver event such as BRCA2 mutation in germline carriers, a diverse and variable number of CN signatures is possible ( Figure S4 ). Exposure to multiple signatures could alter the risk of developing therapeutic resistance, which challenges current therapeutic strategies that target a single process such as HRD.
Future studies on larger sample collections are needed to refine CN signature definitions and interpretation. Application to other tumour types is likely to extend the set of signatures beyond the robust core set identified here. Basal-like breast cancers and lung squamous cell carcinoma, which also have high rates of TP53 mutation and genomic instability (Hoadley et al., 2014) , are promising next targets for our approach. Other limitations are technical: we integrated data from three sources, using three different pre-processing pipelines, and the ploidy determined by different pipelines can have a significant effect on the derived signatures. For example, high-ploidy CN signature 5 was predominantly found in the sequenced samples that underwent careful manual curation to identify whole-genome duplication events. When extending to larger sample sets, a unified processing strategy with correct ploidy determination is likely to produce improved signature definitions.
In summary, our results represent a substantial advance in deconvoluting the profound genomic complexity of HGSOC, allowing robust molecular classification of a disease that lacks classic driver oncogene mutations or recurrent copy-number changes. By dissecting the mutational forces shaping highly aberrant copy-number, our study paves the way to understanding and categorising extreme genomic complexity.
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Figure 2 | Measures for selecting optimal signature number
A comparison of signature number (x-axis) across four measures for determining optimal signature number. The circle and solid lines represent the results from the BriTROC-1 samples run whereas the triangles and dotted lines represent results from 1000 randomly permuted BriTROC-1 matrices (these can be considered a null measure). Here, basis refers to the signature-by-variable matrix, coefficients refers to patient-by-signature matrix, and consensus refers to the connectivity matrix of patients clustered by their dominant signature across 1000 runs. Best-fit is the run that showed the lowest objective score across the 1000 runs. A value of 8 defines the point of stability in the cophenetic, dispersion and silhouette coefficients, and is the maximum sparsity achievable above the null model. 
Methods
Patients and samples
The BriTROC-1 study has been described previously (Goranova et al., 2017) . The study is sponsored by NHS Greater Glasgow and Clyde and ethics/IRB approval was given by Cambridge Central Research Ethics Committee (Reference 12/EE/0349). The study enrolled patients with recurrent ovarian high-grade serous or grade 3 endometrioid carcinoma who had relapsed following at least one line of platinum-based chemotherapy and whose disease was amenable either to image-guided biopsy or secondary debulking surgery. All patients provided written informed consent. Access to archival diagnostic formalin-fixed tumour was also required.
Tagged-amplicon sequencing DNA was extracted from relapsed biopsies and archival diagnostic tissue, and mutation screening of TP53 , PTEN , EGFR , PIK3CA , KRAS and BRAF was performed using tagged-amplicon sequencing as previously described (Goranova et al., 2017) .
Shallow whole genome sequencing (sWGS)
Libraries for sWGS were prepared from 100ng DNA using modified TruSeq Nano DNA LT Sample Prep Kit (Illumina) protocol (Piskorz et al., 2016) . Quality and quantity of the libraries were assessed with DNA-7500 kit on 2100 Bioanalyzer (Agilent Technologies) and with Kapa Library Quantification kit (Kapa Biosystems) using to the manufacturer's protocols. Sixteen to twenty barcoded libraries were pooled together in equimolar amounts and each pool was sequenced on HiSeq4000 in SE-50bp mode.
Deep whole genome sequencing
Deep whole-genome sequencing was performed on 56 tumour and matched normal samples, of which 48 passed quality control. Libraries were constructed with~350-bp insert length using the TruSeq Nano DNA Library prep kit (Illumina) and sequenced on an Illumina HiSeq X Ten System in paired-end 150-bp reads mode. The average depth was 60× (range 40-101×) in tumours and 40× (range 24-73×) in matched blood samples.
Variant calling on mapping quality, base quality, position in read, and strand bias as described (Secrier et al., 2016) . In addition, the blacklisted SNVs from the Sanger Cancer Genomics Project pipeline derived from a panel of unmatched normal samples were used for filtering (Jones et al., 2016) .
Data download
ICGC: Consensus SNVs and INDELs (October 2016 release), consensus structural variants (v 1.6), consensus copy-number calls (January 2017 release), donor clinical (August 2016 v7-2) and donor histology information (August 2016 v7) for 95 ovarian cancer samples were downloaded from the PCAWG data portal. ACEseq copy-number calls were used for analysis. TCGA : ABSOLUTE (Carter et al., 2012) copy-number profiles from Zack et al (Zack et al., 2013) for 402 ovarian cancer TCGA samples were downloaded from Synapse (Schumacher, 2015) . SNVs for these samples were downloaded from the Broad Institute TCGA Genome Data Analysis Center (Broad Institute TCGA Genome Data Analysis Center: Firehose stddata__2016_01_28 run. doi:10.7908/C11G0KM9, Broad Institute of MIT and Harvard). Donor clinical data were downloaded from the TCGA data portal.
Absolute copy-number calling from sWGS After inspection of the TP53 mutation status and relative copy-number profiles of the 300 BriROC-1 sequenced samples, 44 were excluded from downstream analysis for the following reasons: low purity (21), mislabelled (7), pathology re-review revealed sample was not HGSOC (3), no detectable TP53 mutation (13) . Of the remaining samples, 57 showed an over segmentation artefact (likely due to fixation). A more strict segmentation was subsequently applied to these samples to yield a usable copy-number profile. Relative copy-number profiles were generated using QDNAseq (Scheinin et al., 2014) and these were combined with TP53 mutant allele frequency identified using tagged amplicon sequencing in a probabilistic graphical modelling approach adapted from ABSOLUTE (Carter et al., 2012) to generate absolute copy-number profiles. Using Expectation-Maximisation, the model generated a posterior over a range of TP53 copy-number states, using the TP53 mutant allele frequency to estimate purity for each state. The TP53 copy-number state which provided the highest likelihood of generating a clonal absolute copy-number profile was used to determine the final absolute copy-number profile. Following absolute copy-number fitting, the samples were rated using a 1-3 star system. 1-star samples (n=54) showed a noisy copy-number profile and were considered likely to have incorrect segments and missing calls. These were excluded from further analysis. 2-star samples (n=52) showed a reasonable copy-number profile with only a small number of miscalled segments. These samples were used (with caution) for some subsequent analyses. 3-star samples (n=147) showed a high-quality copy-number profile that was used in all downstream analyses. The maximum star rating observed per patient was 15 patients 1-star, 26 2-star, and 91 3-star.
Copy-number signature identification
Preprocessing: 91 3-star BriTROC-1 absolute copy-number profiles were summarised using six different feature density distributions (Outlined in Figure 1B ): 1. segment size -the length of each genome segment in 10MB units; 2. Breakpoint number per 10MB -the number of genome breaks appearing in 10MB sliding windows across the genome; 3. change-point copy-number -the absolute difference in CN between adjacent segments across the genome; 4. segment copy-number -the observed absolute copy-number state of each segment; 5. normalised distance of breakpoints from centromere -the distance of a break from the centromere divided by the length of the chromosome arm; 6. length of segments with oscillating copy-number -a traversal of the genome counting the number of contiguous CN segments alternating between two copy-number states. Each of these distributions was then reduced to a set of five variables encoding the shape of the distribution: the first four moments (mean, variance, skewness and kurtosis) and a fifth variable, Hartigan's dip test (Hartigan and Hartigan, 1985) , which is a measure of the modality of the distribution. As skew can take a negative value, its absolute value was used. All variables were then scaled to lie between (0,1). This approach resulted in a set of 30 variables representing the copy-number profile of each sample.
Signature identification using NMF. The NMF Package in R (Gaujoux and Seoighe, 2010 ) was used to decompose the patient-by-variable matrix into a patient-by-signature and signature-by-variable matrix. A signature search interval of 3-12 was used, running the NMF 1000 times with different random seeds for each signature number. As provided by the NMF Package in R (Gaujoux and Seoighe, 2010) , the cophenetic, dispersion, silhouette, and sparseness coefficients were computed for the signature-by-variable matrix (basis), patient-by-signature matrix (coefficients) and connectivity matrix (consensus, representing patients clustered by their dominant signature across the 1000 runs). 1000 random shuffles of the input matrix were performed to get a null estimate of each of the scores (Figure 2) . We sought the minimum signature number that yielded stability in the cophenetic, dispersion and silhouette coefficients, and that yielded the maximum sparsity which could be achieved without exceeding that which was observed in the randomly permuted matrices. 8 signatures was deemed optimal under these constraints and was therefore chosen for the remaining analysis.
Assigning signature exposures to samples: For the remaining 26 2-star patient samples, and the 82 secondary patient samples (from patients with 2-or 3-star profiles from additional tumours), the LCD function in the YAPSA package in Bioconductor (Huebschmann et al., 2015) was used to assign signature exposures.
Copy-number signature validation
The variable summary procedure described above was applied to copy-number profiles from two independent datasets: 95 whole-genome sequenced (approximately 40×) HGSOC samples processed as part of ICGC Pan-Cancer Analysis of Whole Genomes Project (Campbell et al., 2017) , and SNParray profiling of HGSOC cases as part of TCGA (Zack et al., 2013) . The number of signatures was fixed at 8 for matrix decomposition with NMF. A Pearson correlation coefficient was obtained by correlating the signature by feature matrix from each cohort with one derived from the high-quality sWGS copy-number profiles.
Identification of copy-number signature patterns
The density distributions appearing in Figure S5 were used to assist with determining important patterns associated with each signature. These were generated using a weighted kernel density estimator in R where the copy-number features were weighted by their signature exposures for 117 BriTROC-1 cases. We used these, in combination with the variable weights for each signature (Figure 6 ), to determine which parts of each distribution were important for defining each signature.
Survival analysis
Overall survival in BriTROC-1 patients was calculated from the date of enrolment to the date of death or the last documented clinical assessment, with data cutoff at 1 December 2016. Given that the BriTROC-1 study only enrolled patients with relapsed disease, it was necessary to left truncate the overall survival time. In addition, cases where the patient was not deceased were right censored. Survival data for the ICGC and TCGA cohorts were right censored as required (left truncation was not necessary). The combined samples were split into training (100% BriTROC-1, 50% ICGC and 50% TCGA = 356) and test (50% ICGC and 50% TCGA = 246) cohorts. All of the BriTROC-1 samples were used in the training set to avoid issues calculating prediction performance on left-truncated data. A Cox proportional hazards model was fitted on the training set, with the signature exposures as covariates, stratified by cohort (BriTROC-1, OV-AU, OV-US, TCGA) and age (<51; 52-59; 60-69; >70), using the survival package in Bioconductor (Therneau, 2000) . As the signature exposures summed to 1, signature 2, which demonstrated the lowest variance across patients was excluded. After fitting, the model was used to predict risk in the test set and performance was assessed using the concordance index calculation in the survcomp package in Bioconductor 42 . An alternative survival analysis approach was also applied, where the maximum signature exposure in each patient was used to assign a patient to either a good prognosis group (signature 1, 7, or 8) or a poor prognosis group (signature 2,3,4,5,6) . A second Cox proportional hazards model was fitted on the training set using the groups as covariates to determine a log-rank score. The survfit function was used to generate a Kaplan-Meier plot for the grouping. The survdiff function was used test the performance of this approach in the test set and the survfit function used to generate Kaplan-Meier curves ( Figure S1 ).
Association of copy-number signature exposures with other features
Of the 48 deep WGS BriTROC-1 samples, 44 had matched 2-and 3-star sWGS copy-number profiles. As the signature exposures from the sWGS were used for analysis, associations were made only with these 44 samples.
Mutational signatures. For 44 deep WGS BriTROC-1 samples and 95 ICGC samples, motif matrices were extracted using the SomaticSignatures R package (Gehring et al., 2015) and the weights of known COSMIC signatures were determined using the deconstructSigs R package Figure S1 | Survival analysis of patients stratified by dominant signature exposure Kaplan-Meier curves of overall survival probabilities for patients in A training cohort and B test cohort. Each cohort was divided into two groups based on the patients' maximum observed signature exposure (Red: maximum observed signature exposure for signatures 2,3,4,5, or 6; Black: maximum observed signature exposure for signatures 1,7 or 8) . Black dotted lines indicate the median survival for each group. The p-values reported are from a log-rank test. Shaded areas represent 95% confidence intervals. Below B is a table specifying the number of remaining cases at risk every 500 days. These is no at risk table for A as the BriTROC-1 cases have left truncated survival.
Figure S2 | Correlation plots of signature exposures with other features and SNV signatures
Feature values (right) versus signature exposures (top). Blue lines represent a linear model fit and shading around the lines represent the 95% confidence interval. Shaded panels represent results which are significantly correlated (adjusted P<0.1).
Figure S3 | Differences in exposures between cases with mutated pathways versus wild-type
Boxplots representing the signature exposures of cases with mutations (mut) in a given pathway (top) versus those with wild-type alleles (wt). The box widths are proportional to the number of cases (exact numbers can be found in Figure 5 ). Shaded panels indicate significant differences (adjusted P<0.1, values found in Table S4 ). 
Figure S5 | Overview of copy-number feature distributions
Separate density distributions are plotted for each copy-number feature across all of the signatures. The distributions that have highly weighted variables (see Figure 6 ) for each of the feature distributions are coloured.
